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Inflammatory breast cancer (IBC) is an aggressive and invasive tumor, accounting for 2.5%of all breast cancer cases,
and characterized by rapid progression, regional and distant metastases, younger age of onset, and lower overall
survival. Presently, there are no effective therapies against IBC and a paucity of model systems. Our aim was to
develop a clinically relevant IBC model that would allow investigations on the role of chemokine receptors in IBC
metastasis. Primary cultures of tumor cells were isolated from pleural exudates of an IBC patient and grown as
spheres or monolayers. We developed a human xenograft model where patient-derived IBC cells, stably transduced
with lentiviral vectors expressing fluorescent and bioluminescent markers, were inoculated directly into the left
ventricle of mice. Our in vivo data show that these IBC cells (FC-IBC02A) are able to seed and proliferate into various
organs, including brain, lungs, lymph nodes, and bone, closely replicating the metastatic spread observed in IBC
patients. Moreover, cells were able to generate tumors when grafted in the mammary fat pad of mice. RT-PCR and
microscopy studies revealed expression of both CXCR4 and ACKR3 receptors in FC-IBC02A cells. Furthermore,
CXCL12 (the endogenous chemokine ligand of these receptors) induced transendothelial migration of these cells
and stimulated signaling pathways involved in cell survival and migration - an effect reduced by CXCR4 or ACKR3
antagonists. This newmodel can be used to develop chemokine-based pharmacological approaches against the IBC
metastatic process. This work also provides the first evidence of ACKR3 expression in IBC cells.
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Inflammatory breast cancer (IBC) is an aggressive and rare form of
invasive breast cancer that presents with very distinct clinical andReceived 23 June 2015; Revised 20 July 2015; Accepted 29 July 2015
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http://dx.doi.org/10.1016/j.tranon.2015.07.002pathological features [1]. Clinical symptoms of IBC are most
frequently associated with acute onset of edema, erythema, and an
orange-peel (peau d'orange) appearance of the overlying skin in then
).
Figure 1. In vitro/in vivo model of IBC: (A) Human IBC-cells (FC-IBC02A) were cultured as monolayer or spheres. Sphere-derived and
monolayer FC-IBC02A cells were engineered to stably express enhanced Green Fluorescent Protein (eGFP) as detailed in themethods. (B)
Sphere-derived cells and monolayer eGFP-FC-IBC02A cells were both able to spread to and proliferate in brain and bones (250,000 cells
were injected intracardially). For bones: cells were consistently detected along the growth plate in femora and tibiae. Longer term in vivo
studies (2 and 4 weeks) showed the proliferative capability of disseminated IBC-cells. N = 3 animals (4 foci); data shown as mean ± SEM.
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discrete palpable mass, IBC is often misdiagnosed upon clinical
examination [1]. Furthermore, due to the invasion of tumor cell
aggregates into lymphatic channels, IBC presents peculiar features
that can mimic an acute inflammation [2]. Although it is estimated
that IBC accounts for about 2.5% of all breast cancer cases in the
United States, patients diagnosed with IBC have the worst prognoses
and continue to have poorer survival outcomes compared with
patients with other variants of the disease [3,4]. Even with the
addition of multimodal therapies consisting of neo-adjuvant
chemotherapy followed by surgery and radiotherapy, 5-year overall
survival rates reach at best 25-28% [5,6]. This is in part due to IBC's
high metastatic potential and propensity to invade blood vessels [2].IBC patients have shown a disposition to develop metastases in the
brain, bones, and various visceral organs [5].
There is increasing evidence that the expression of select
chemokine receptors play an important role in breast cancer
metastasis and prognosis [7–11]. Among them, the G protein-
coupled receptor CXCR4 and its activating ligand CXCL12 (also
known as stromal derived factor-1α) have been shown to be
overexpressed in over 20 different tumor types [12]. Furthermore,
enhanced expression of CXCR4 has been directly correlated with
poor overall survival in metastatic breast carcinomas [13]. The
recently identified chemokine receptor ACKR3, formerly known as
CXCR7, also plays a role in CXCL12/CXCR4 signaling [14]. This
atypical chemokine receptor can act as a CXCL12 scavenger, signal
Figure 2. In vivo bioluminescence model: (A) Tumors development in vivo was followed by bioluminescence over a course of 14 weeks.
The eGFP-luciferase cell line was obtained by infecting eGFP-FC-IBC02A cells with a Red Firefly Luciferase expressing lentivirus; 250,000
cells were injected intracardially. (B) Nine out of ten mice inoculated with FC-IBC02A cells developed tumors. (C) Total tumor burden was
quantified using Living Image Software (Caliper Life Sciences) and data are shown asmean ± SEM (total flux [p/s]). N = 9 animals. Graphs
in B/C include data from various organs.
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responses through direct or indirect interactions [15–17]. The
downstream pathways of CXCR4 are important for the proliferation,
survival, and migration of cancer cells [12,18]. Tumor cells that
overexpress CXCR4 co-opt the chemokine system normally used by
leukocyte trafficking in order to migrate to organs that secrete high
concentrations of CXCL12 such as the brain, lungs, liver, and bone
marrow. CXCR4 also facilitates primary tumor growth through
promoting angiogenesis via up-regulation of VEGF and recruitment
of endothelial progenitor cells [12]. Considering the impact of
metastasis in the overall survival of IBC patients, a better
understanding of the metastatic process is essential to develop
effective therapeutic strategies. Thus, preclinical models that predict
patient response, mimic complex and tissue-specific patterns of
metastasis, and enable early accurate detection of secondary lesions are
greatly needed. To this end, using a cell line obtained from the pleural
exudate of an IBC patient, we recently developed a preliminary in
vivo model of IBC [19]. Here, we present a refined version of this
model that allows study of early as well late stage IBC metastases and
of the involvement of CXCR4/ACKR3 in this process. Our approach
introduces a visual advantage in identifying individual disseminated
tumor cells (DTCs) of IBC origin with the use of fluorescent labeling,thus allowing investigations on the early stages of the in vivo
dissemination process driven by these cells. Long-term monitoring of
tumor progression is afforded by the simultaneous expression of the
luciferase gene. We also characterized expression and function of
critical chemokine receptors in the IBC cells. Overall, our data suggest
that these cells are an excellent tool for both in vitro and in vivo
investigations concerning the roles of the CXCL12-CXCR4/ACKR3
axis in IBC migration, growth, and invasion.
Materials and Methods
Cell Cultures
Human primary IBC cells (FC-IBC02A) were isolated from the
pleural exudate of an IBC patient and cultured as monolayer or
mammospheres. The patient had signed an informed consent from
the Fox Chase Cancer Center (FCCC) Human Subject Protection
Committee prior to sample collection. Both the Research Review
Committee (RRC) and the Institutional Review Board (IRB) at
FCCC approved the study (approval #10-826). Cells in monolayer
were grown in DMEM containing 10% fetal bovine serum (Hyclone,
Logan, UT, USA) and 0.1% gentamicin (Invitrogen, Carlsbad, CA)
and kept at 37°C and 5% CO2. Spheres were grown in suspension
Table 1. Metastatic spread of FC-IBC02A via intracardiac injection route.
Tumor Location Mouse1 Mouse2 Mouse3 Mouse4 Mouse5 Mouse6 Mouse7 Mouse8 Mouse9 Mouse10 *
Brain - - - - - - 1 - - -
Knee joint - - - 1 - - - - - 1
Lymph node 1 - 1 1 1 - - - 1 -
Adrenal gland - - 1 - - 1 - 1 1 -
* This animal was sacrificed at 10 weeks.
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Epithelial Cell Growth Medium, MEGM) containing: Mammary
Epithelial Cell Basal Medium (MEBM), 2% B27 supplement,
heparin (4 μg/ml), recombinant human bFGF (20 ng/ml), and EGF
(20 ng/ml), and an antibiotics-antimycotic solution composed of
Streptomycin, Amphotericin B, and Penicillin (Gibco, 15240, Grand
Island, NY). FC-IBC02A cells were stably transduced with lentiviral
vectors expressing constitutive eGFP (Lentivector: pHRCMVO2-
EFtet from AmeriPharma) [20] and luciferase, produced by
subcloning the Red Firefly Luciferase gene (from pMCS-Red Firefly
Luc; Thermo Fisher Scientific, Waltham, MA) into the BamH1 and
Xho1 sites of pENTR1A no ccDB (Addgene, Cambridge, MA) then
transferred via Gateway LR Clonase II (Thermo Fisher) into pLenti
CMV puro DEST (Addgene) these cells were used for both in vitro
and in vivo experiments. FC-IBC02A cells were authenticated for
human origin and gender by IDEXX Laboratories, Columbia, MO
(case number: 18505-2012).
Primary human brain microvascular endothelial cells (HBMECs)
were purchased from ScienCell (Carlsbad, CA). HBMEC were grown
in Endothelial cell medium (ECM, ScienCell) in tissue culture flasks
coated with Fibronectin (Cell Systems). Cells were passaged according
to the manufacturer's instructions and used up to passage eight.
Immunocytochemistry
Monolayer cells on coverslips and spheres on chamber slides were
fixed in 4% paraformaldehyde. Cells were then permeabilized with
0.1% Triton X-100 for 5 minutes. The following antibodies were
used: mouse anti-ACKR3 (clone 11G8; 50 mg/mL—a gift from
ChemoCentryx), mouse anti-CXCR4 (clone 12G5; 1:200—R&D
Systems, Minneapolis, MN). Confocal images were captured with a
Zeiss LSM5 Exciter laser scanning confocal microscope (Thornwood,
NY) using sequential imaging to prevent interchannel cross-excitation
between fluorochromes.
RT-PCR
Total RNA was extracted using the RNeasy mini kit (Qiagen,
Valencia, CA). RNA obtained from human cells was treated with
DNase prior to RT reaction.
cDNA was synthesized from total RNA. The following primers
were used for amplification. CXCR4: 5′-GGCCCTCAAGACCA
CAGTCA-3′ and 5′-TTAGCTGGAGTGAAAACTTGAAG-3′;
ACKR3: 5′-ACGTGGTGGTCTTCCTTGTC-3′ and 5′-AAGGC
CTTCATCAGCTCGTA-3′; CXCL12: 5′-ATGAACGCCAA
GGTCGTGGTC-3′ and 5′-CTTGTTTAAAGCTTTCTCCAGG
TACT-3′; human 28S: 5′-GTTCACCCA CTAATAGGGAA
CGTGA- 3′ and 5′-GGATTCTGACTTAGA GGCGTTCAGT-3′.
PCR was performed as follows: 5 minutes at 94°C, 35 cycles of 30 s at
94°C, 30 s at 60°C, and 30 s at 72°C, followed by 7 min at 72°C. For
gel electrophoresis analysis, each amplicon was generated and
visualized using ethidium bromide staining after electrophoresis on
a 1.8 % agarose gel. Human 28S was used as loading control.Western Blot
Cells were washed with ice-cold balanced salt solution and scraped in
lysis buffer (50 mM Tris, 150 mM NaCl, 0.5% sodium deoxycholate,
0.1% sodium dodecyl sulfate [SDS], 10 mM Na4P2O7, 5 mM
ethylenediaminetetra-acetic acid [EDTA], 1% Triton X-100, 1 mM
dithiothreitol, with protease (Calbiochem, cat#539134) and phosphatase
(Calbiochem, cat#524625) inhibitor cocktails). Equal amounts of
proteins as determined by the bicinchoninic acid assay from Thermo
Scientific (Rockford, IL) were loaded in each lane, separated by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), and
transferred to polyvinylidene fluoride membranes for immunoblotting.
The following primary antibodies were used: anti-pERK1/2 (1:1000,
cat#9101, Cell Signaling, Danvers, MA), anti-ERK1/2 (1:1000,
cat#9102, Cell Signaling). Anti-actin was used for loading control
(1:5000, Sigma-Aldrich).
Transendothelial Migration
Transendothelial migration of FC-IBC02A cells was performed
using HTS FluoroBlok 8.0 μm colored PET Membrane Inserts for
24-well plates (BD Falcon). 50,000 HBMECs were added to
fibronectin-coated 24-well (overnight coating) inserts and grown for
at least 5 days in 5% CO2 at 37°C. The medium was replaced every
day with fresh medium. Before cell migration assays were performed,
the integrity of the cell monolayer was confirmed by monitoring of
Trans-endothelial electrical resistance (TEER), measured with an
Epithelial Voltohmmeter (EVOM,World Precision Instruments). To
obtain TEER values in Ω × cm2, the mean resistance of an empty
insert was subtracted from the mean resistance of the insert with
cultured cells (3 readings per insert). This value was then multiplied
by the surface area of the insert (0.33 cm2). eGFP-FC-IBC02A cells
(2×105) in 1% FBS, 0.1% BSA DMEM were seeded in the upper
chamber, and 1% FBS, 0.1% BSA DMEM supplemented with
20 nM CXCL12 was applied in the lower chamber. After 8 and 24
hours, transmigrated cells were detected and counted using a digital
inverted fluorescence microscope (Evos, AMG, Bothell, WA). For
each insert, the entire surface area was counted.
In Vivo Tumorigenicity
To test the ability of monolayer and sphere-derived FC-IBC02A
cells to initiate tumor in vivo, monolayer (1×106) or sphere (1×105)
dissociated FC-IBC02A cells were resuspended in 100 μL of
DMEM/F12 + 100 μL of matrigel (BD Biosciences) and injected
into the mammary fat pad of 6–8 weeks old female immunocom-
promised (CB17-SCRF) mice under anesthesia (ketamine 80 mg/kg
and xylazine 10 mg/kg). CB17-SCRF mice were obtained from
Taconic (Germantown, NY, USA) and housed in a germ-free barrier.
Mice were monitored for disease symptoms and were sacrificed by
CO2 asphyxiation when they showed weight loss or any severe sign of
disease (8-10 days post injections). Tumors were removed, fixed in
formalin, paraffin-embedded, and then stained with hematoxylin-
eosin (H&E) for histopathology (n = 3 for each condition).
Figure 3. Dissemination of FC-IBC02A cells in different organs: Mice were sacrificed after 14 weeks and tissue sections of various organs
were obtained as described in the methods. Tumors were found in the brain, adrenal glands, bones, and lymph nodes. Representative
fluorescent images of tissue sections confirm the presence of FC-IBC02A in vivo.
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CB17-SCRF female mice were anesthetized as indicated above and
then inoculated in the left cardiac ventricle with either monolayer or
sphere-derived human IBC-cells, as we previously described for other
cell types [21]. Briefly, cell inoculation was performed using an insulin
syringe with a 30-gauge needle. The correct execution of intracardiac
inoculation was established by the appearance of fresh arterial blood in
the Luer-Lok fitting of the hypodermic needle, which indicated the
successful penetration of the ventricular wall. In addition, blue
fluorescent polystyrene beads (10 μm diameter, Invitrogen-Molecular
Probes) were co-injected with cancer cells. Their detection by
fluorescence microscopy in different organs at necropsy confirmed
the successful inoculation in the blood circulation. We used 250,000
cells in a total volume of 100 μL of DMEM/F12. Dissemination of
cancer cells to the brain, bones and other organs was studied at
10 minutes, 2 weeks, 1 month, and then up to 14 weeks post
inoculation. All experiments were performed in accordance with NIH
guidelines for the humane use of animals. All protocols involving the
use of animals were approved by the Drexel University College of
Medicine Committee for the Use and Care of Animals.
Tissue Preparation and Cancer Cell Detection
Continuous long-term in vivo monitoring of bioluminescence was
performed using the IVIS Lumina XR (PerkinElmer, Waltham, MA).
Mice were administered weekly via i.p. with D-Luciferin, K+ Salt
Bioluminescent Substrate (PerkinElmer, Waltham, MA) and analysis
was completed using Caliper Life Science's Living Image software.
Animals were sacrificed and tissues were fixed, decalcified in 0.5 M
EDTA if necessary and frozen in O.C.T. embedding medium
(Electron Microscopy Sciences, Hatfield, PA, USA). Serial tissue
sections of 80 μm in thickness were obtained using a Microm
HM550 cryostat (Mikron, San Marcos, CA). Sections of each
soft-tissue organs and hind legs were transferred on glass slides, stored
at −20°C and examined for cancer cells using a Zeiss AX70
microscope (Carl Zeiss, Oberkochen, Germany) connected to a
Nuance Multispectral Imaging System (CRI, Guelph, ON). Digitalimages were analyzed and processed with the Nuance Software
(v. 2.4). Microscope and software calibration for size measurement
was regularly performed using a TS-M2 stage micrometer (Oplenic
Optronics). Bright field and fluorescence images were acquired with
an Olympus DT70 CCD color camera.
Statistical Analysis
Statistical significance was calculated using two-tailed t test or
one-way ANOVA. All data are reported as the mean ± SEM. A
P value of ≤ .05 was considered statistically significant.
Results and Discussion
StemCell Properties andMetastatic Behavior of Cultured IBCCells
Human primary IBC cells (FC-IBC02A) were isolated from the
pleural exudate of an IBC patient, as previously reported [19], and
engineered to stably express green fluorescence protein (GFP) using a
lentiviral vector (Figure 1A). Cells were cultured as either monolayer or
mammospheres. Both types of cultures expressed E-cadherin, an
adhesion protein particularly abundant in invasive IBC cells and critical
to its invasive andmetastatic phenotype [1,22]—these data are reported
in panel A of the Supplementary Figure 1. E-Cadherin overexpression
in IBC cell types is known to be essential for its metastatic phenotype
and its ability to form tumor emboli [23,24]. Normally, a loss of
E-cadherin has been shown to promote cell invasiveness and be a
fundamental event in the epithelial-mesenchymal transition, however,
there is evidence to suggest that this loss of epithelial morphology is not
a requirement for the invasion and metastasis of various carcinomas
[25]. The expression of E-cadherin in monolayer and sphere-derived
FC-IBC02A cells may fall in this paradigm.
We also evaluated the expression of CD44, a cancer stem cell marker.
Monolayer-derived cells showed a weak to absent expression of CD44,
which was strongly expressed in the spheres (Supplementary Figure 1A).
However, IBC monolayers cells were able to transition to the sphere
form upon the addition of MEGM (Supplementary Figure 1B)—
suggesting that they retain stem cell potential. Clinically, this may be
Figure 4. Expression of CXCR4 and ACKR3 in FC-IBC02A cells: (A) Reverse-Transcription PCR analysis showing the mRNA expression of
the chemokine receptors CXCR4 and ACKR3 and their ligand CXCL12 in FC-IBC02A cells in monolayer (left) and spheres (right). (B)
Representative confocal microscopy micrographs of eGFP-FC-IBC02A-cells in monolayers (left) and spheres (right). Cells expressed
CXCR4 (mouse monoclonal antibody, clone 12G5, red, top) and ACKR3 (mouse monoclonal antibody, clone 11G8, green, middle). A
negative control without primary antibodies is shown (bottom). (C) CXCR4 appeared to be localized predominantly to the cellular
membrane, while ACKR3 displayed a marked expression in the cytoplasm. Combined merge image show areas of CXCR4 and ACKR3
co-localization. Results are from two independent experiments.
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In linewith this observation, in vivo experiments showed the development
of tumors after injection of either monolayer (106 cells) or dissociated
spheres (105 cells) into the mammary fat pad of 6 to 8 week-old female
mice (Supplementary Figure 2A). Other studies have also suggested that
CD44+/CD24−/low breast cancer cells exhibit a greater tendency to
generate distant metastases [28,29]. Therefore, this transition from
CD44− to CD44+ may also play an active role in FC-IBC02A's ability to
invade. In any case, as the two cellular models share similar in vivo
properties, this defining featuremay facilitate follow-up studies as cells can
be rapidly converted from spheres to monolayer and back.
To assess theirmetastatic potential, we delivered IBC cells directly into
the arterial blood circulation via the left cardiac ventricle. The delivery of
cancer cells via this route generates circulating tumor cells that rapidly
disseminate to skeletal and soft-tissues, closely replicating the distantspreading of primary solid tumors in humans [30]. Tumor cells, cultured
as a monolayer, disseminated to areas of known CXCL12 abundance
[31,32], including the brain, bones, (Figure 1B), lymph nodes, adrenal
glands and the lungs (not shown). Ten minutes after the inoculation of
FC-IBC02A cells, DTCs were detected along the growth plates of the
distal femur, proximal tibia, and brain tissue (Supplementary Figure 2B).
Longer term in vivo studies (2 and 4weeks) were completed to determine
the survival and proliferative potential of disseminated IBC cells in these
secondary locations. Tumor foci measuring 1167.68μm2 (±265.49, n =
4) and 5948.68 μm2 (±1616.78, n = 4), respectively, were observed in
the bone at 2 and 4weeks post-inoculation (Figure 1B). A similar pattern
of dissemination and colonization was found in the brain, where DTC
lesions reached an average size of 1400.23 μm2 (±400.65, n = 5) at 4
weeks. Similar results were obtained using sphere-derived FC-IBC02A
cells (not shown).
Figure 5. Stimulation of CXCR4 and ACKR3 in FC-IBC02A cells—(A) CXCL12-induced ERK1/2 phosphorylation. Cell lysates from untreated
cultures (ctr) or cultures treated with 20 nM CXCL12 for different times were collected and analyzed by electrophoresis followed by
Western blotting. Blots were probed with anti–phospho-ERK1/2 (top panels), by anti–ERK1/2 (middle panel) and anti-actin antibodies
(bottom panels) as a loading control. Densitometric analysis showed significant differences in pERK bands after CXCL12 treatment (peak
at 15′ for monolayer cells, 10′ for sphere-derived cells) compared with control. Total ERK was used for normalization of pERK. Data
represent the mean ± SEM, as obtained in at least three independent experiments. (B) CXCL12-induced transendothelial migration. After
8 and 24 hours of exposure to 20 nM CXCL12, transmigrated cells were detected and counted by digital inverted fluorescence
microscopy. N = 5, *P b .05, **P b .01, ***P b .001.
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course of 14 weeks using FC-IBC02A cells expressing both luciferase
and GFP, as indicated in the methods. Bioluminescence was first
detected at 5 weeks, measured by total flux, and monitored weekly over
the whole course of the study (Figure 2A). One mouse was sacrificed
early, at week 10, and thus there is no data available for this animal at
week 14. However, in total, nine of ten mice developed bioluminescent
signal and were found positive for lesions via tissue sectioning
(Figure 2B). By using in vivo bioluminescence imaging, individual
lesions were followed longitudinally. Total flux per animal is normalized
and shown in Figure 2C. Average tumor burden of each animal at 5
weeks was measured to be 4.601e+05 (±2.12e+05, n = 9) [photons/
second], at 8 weeks total flux was at 1.585e+06 (±6.52e+05, n = 9) [p/s],
at 10 weeks measured at 4.278e+06 (±2.11e+06, n = 9) [p/s], and at
14 weeks it was measured to be 3.737e+07 (±2.01e+07, n = 9) [p/s].
At the end of the observation period, animals were sacrificed and
dissection was guided by bioluminescence results; tissues were fixed in
4% paraformaldehyde and sectioned. Using fluorescence, biolumines-
cent signals were confirmed for lesions in the lymph nodes, brain,
knee-joints, and adrenal glands (Table 1).Multispectral imaging analysisallowed for GFP labeled FC-IBC02A cells to be discretely isolated from
background noise and tumor size accurately measured (Figure 3).
Expression of Functional CXCR4 and ACKR3 in IBC Cells
Previous studies suggested key roles of CXCR4 and ACKR3 in
breast cancer progression and metastasis [33,34]. Therefore, it was
important to investigate expression of these chemokine receptors in
the FC-IBC02A cells. RT-PCR studies showed presence of both
CXCR4 and ACKR3 transcripts in these cells (Figure 4A). The cells
also expressed their chemokine ligand, CXCL12, indicative of
possible autocrine/paracrine signaling.
To gain further insight into the cellular localization of the CXCR4 and
ACKR3 proteins in the FC-IBC02A cells, immunocytochemistry and
confocal microscopy were used. CXCR4 is recognized as the main
signaling receptor mediating the biological actions of its only chemokine
ligand, CXCL12, whereas ACKR3 primarily acts as a scavenger receptor
and regulator of CXCR4 function [35,36]. As shown in Figure 4B, under
basal conditions, CXCR4 staining was predominantly localized to the cell
membrane while ACKR3 was expressed more diffusely, i.e. both at
plasma membrane level and in the cytoplasm. Additionally, the ACKR3/
Figure 6. CXCL12-induced ERK1/2 phosphorylation is reduced by inhibition of CXCR4 and ACKR3. FC-IBC02A IBC-cells were treated with
the CXCR4 inhibitor AMD3100 (10 μg/mL) or the ACKR3 ligand CCX733 (1 μM) 15 minutes before (and during) their exposure to vehicle or
CXCL12 (20 nM, as indicated). Densitometric analysis showed a reduction in pERK bands after AMD3100 or CCX733 treatment compared
with CXCL12 alone. Total ERK was used for normalization of pERK. Data represent the mean ± SEM, as obtained in three or more
independent experiments. Images are representative of the same experiment. *P b .05, **P b .01, ***P b .001.
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associations between the two receptors (Figure 4C) and consistent with
previous studies, from our group and others, supporting CXCR4/
ACKR3 cellular interactions [16,35].
To confirm function of the chemokine receptors in the
FC-IBC02A cells, we measured the activation of a typical signaling
pathway downstream of CXCR4, i.e., the extracellular regulated
kinases 1/2 (ERK1/2). Cell lysates from FC-IBC02A cultures treated
with CXCL12 (20 nM)—or vehicle (0.1% BSA/PBS)—were
analyzed by Western blot, using antibodies that selectively recognize
the total or phosphorylated form of ERK1/2 proteins. As indicated in
Figure 5A, quantitative analysis showed significant increases of
phospho-ERK1/2 after exposure (10, 15, or 30 minutes) of either
monolayer or sphere-derived cells to CXCL12, confirming stimula-
tion of CXCR4 in these cells regardless of culture conditions. Next,
we evaluated the ability of CXCL12 to stimulate migration of
FC-IBC02A cells. To simulate in vivo conditions, a transendothelial
migration assay was performed using HBMECs as described in the
methods. FC-IBC02A cells were plated on one side of a transwell and
CXCL12 (20 nM) was added to the other. An increase in the number
of transmigrated cells was seen at both 8 and 24 hours (Figure 5B) in
the presence of CXCL12. Overall, these findings are consistent withthe observed CXCR4 expression and the previous reports regarding
CXCL12-induced signaling [37].
Antagonists of CXCR4 and ACKR3 Inhibit CXCL12 Signaling
in IBC Cells
We next investigated whether treatment with specific chemokine
receptor antagonists would inhibit the intracellular signaling
pathways stimulated by CXCL12. Thus, prior to exposure of cells
to CXCL12, they were treated for 15 minutes with AMD3100
(CXCR4 antagonist) or CCX733 (ACKR3 antagonist) [38,39]. Our
data show a marked decrease in ERK1/2 activation in cells co-treated
with AMD3100 and CXCL12 (20 μM). Pre-treatment with
CCX733 (1 μM) also decreased ERK activation (Figure 6). Thus,
similarly to other cell types, CXCR4 and ACKR3 are both involved in
CXCL12-induced responses in FC-IBC02A cells.
Conclusion
In summary, the in vitro and in vivo data presented here show that
FC-IBC02A cells represent an excellent, clinically relevant model to
characterize the role of chemokine receptors in the IBC metastatic
process. Importantly, FC-IBC02A secondary lesions detected in our
pre-clinical model replicate patterns of distant dissemination observed
366 Wurth et al. Translational Oncology Vol. 8, No. 5, 2015in IBC patients as shown by axillary lymph node involvement, brain,
and bone metastases. The genomic profile of these cells [19] aligns
well with their metastatic behavior.
The combined bioluminescence/fluorescence approach described
here provides an advantage for longitudinal tracking of individual
tumor development that can also serve as a guide during tissue
dissection. At the same time, the high sensitivity of advanced
multispectral image analysis allows detection of microscopic lesions
(made of isolated cells or clusters of few cells), which is instrumental
to identification of therapeutic approaches that can interfere with
critical steps involved in arrival and survival of circulating tumor cells
into the metastatic niche.
Metastatic dissemination of solid tumors is thought to depend on
expression of chemokine receptors [7,40]. Although CXCR4 and
ACKR3, which are known to regulate cell migration and survival, have
been previously implicated in various forms of cancer [41–43], there is
very limited knowledge of the involvement of these receptors in IBC,
due to the rarity of the disease and the paucity of cellular models
available. This work describes an accurate, systematic model to study
IBC progression and the very first evidence of ACKR3 expression in
IBC cells. Thus, it provides the foundation for further characterization
of the role of chemokine receptors in the progression of IBC disease and
any other translational investigations focused on development of
targeted therapies for this aggressive form of breast cancer.





RW characterized the properties of the FC-IBC02A cells in
culture, determined expression and function of chemokine
receptors in vitro, and carried out the shorter term in vivo studies;
KT generated the cells stably expressing GFP and Luciferase,
performed the long-term in vivo studies, and assembled a first draft
of the manuscript; DJ participated to the generation of the GFP+
cells and performed initial intra-cardiac injections; SVF and MC
isolated the FC-IBC02A cells, established the cultures, and
provided relevant clinical data; AF generated the animal model
of metastasis and participated to the design of the in vivo studies;
OM conceived and designed the overall study, analyzed the data
(with RW, KT, and AF), wrote the manuscript, and supervised/
coordinated all phases of research. All authors have read and
approved the final manuscript.
Acknowledgments
The authors wish to thank Dr. Mark Penfold (ChemoCentryx) for
the anti-ACKR3 antibody and CCX733, and the NIH
(R01DA15014 to OM) and the PA Breast Cancer Coalition
(Refunds for Research Grant to AF) for their support. RW was the
recipient of a post-doctoral FIRC fellowship (2012-13).
References
[1] Robertson FM, BondyM, and YangW, et al (2010). Inflammatory breast cancer:
the disease, the biology, the treatment. CA Cancer J Clin 60(6), 351–375.
[2] Kleer CG, van Golen KL, and Merajver SD (2000). Molecular biology of breast
cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular
determinants. Breast Cancer Res 2(6), 423–429.[3] Hance KW, Anderson WF, and Devesa SS, et al (2005). Trends in inflammatory
breast carcinoma incidence and survival: the surveillance, epidemiology, and end
results program at the National Cancer Institute. J Natl Cancer Inst 97(13),
966–975.
[4] Dawood S and Cristofanilli M (2011). Inflammatory breast cancer: what progress
have we made?Oncology (Williston Park) 25(3), 264–270 [273].
[5] Ueno NT, Buzdar AU, and Singletary SE, et al (1997). Combined-modality
treatment of inflammatory breast carcinoma: twenty years of experience at M. D.
Anderson Cancer Center. Cancer Chemother Pharmacol 40(4), 321–329.
[6] Low JA, Berman AW, and Steinberg SM, et al (2004). Long-term follow-up for
locally advanced and inflammatory breast cancer patients treated with
multimodality therapy. J Clin Oncol 22(20), 4067–4074.
[7] Muller A, Homey B, and Soto H, et al (2001). Involvement of chemokine
receptors in breast cancer metastasis. Nature 410(6824), 50–56.
[8] Cabioglu N, Gong Y, and Islam R, et al (2007). Expression of growth factor and
chemokine receptors: new insights in the biology of inflammatory breast cancer.
Ann Oncol 18(6), 1021–1029.
[9] Burger JA and Kipps TJ (2006). CXCR4: a key receptor in the crosstalk between
tumor cells and their microenvironment. Blood 107(5), 1761–1767.
[10] Liang Z, Wu T, and Lou H, et al (2004). Inhibition of breast cancer metastasis
by selective synthetic polypeptide against CXCR4. Cancer Res 64(12),
4302–4308.
[11] Salmaggi A, Maderna E, and Calatozzolo C, et al (2009). CXCL12, CXCR4 and
CXCR7 expression in brain metastases. Cancer Biol Ther 8(17), 1608–1614.
[12] Domanska UM, Kruizinga RC, and Nagengast WB, et al (2013). A review on
CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 49(1),
219–230.
[13] Li YM, Pan Y, and Wei Y, et al (2004). Upregulation of CXCR4 is essential for
HER2-mediated tumor metastasis. Cancer Cell 6(5), 459–469.
[14] Bachelerie F, Graham GJ, and Locati M, et al (2014). New nomenclature for
atypical chemokine receptors. Nat Immunol 15(3), 207–208.
[15] Bachelerie F, Ben-Baruch A, and Burkhardt AM, et al (2014). International
Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the
extended family of chemokine receptors and introducing a new nomenclature for
atypical chemokine receptors. Pharmacol Rev 66(1), 1–79.
[16] Levoye A, Balabanian K, and Baleux F, et al (2009). CXCR7 heterodimerizes
with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood
113(24), 6085–6093.
[17] Luker KE, Steele JM, and Mihalko LA, et al (2010). Constitutive and
chemokine-dependent internalization and recycling of CXCR7 in breast cancer
cells to degrade chemokine ligands. Oncogene 29(32), 4599–4610.
[18] Busillo JM, Armando S, and Sengupta R, et al (2010). Site-specific phosphorylation
of CXCR4 is dynamically regulated by multiple kinases and results in differential
modulation of CXCR4 signaling. J Biol Chem 285(10), 7805–7817.
[19] Fernandez SV, Robertson FM, and Pei J, et al (2013). Inflammatory breast
cancer (IBC): clues for targeted therapies. Breast Cancer Res Treat 140(1), 23–33.
[20] Liu Q, Russell MR, and Shahriari K, et al (2013). Interleukin-1beta promotes
skeletal colonization and progression of metastatic prostate cancer cells with
neuroendocrine features. Cancer Res 73(11), 3297–3305.
[21] Russell MR, Liu Q, and Fatatis A (2010). Targeting the {alpha} receptor for
platelet-derived growth factor as a primary or combination therapy in a preclinical
model of prostate cancer skeletal metastasis. Clin Cancer Res 16(20), 5002–5010.
[22] Dong HM, Liu G, and Hou YF, et al (2007). Dominant-negative E-cadherin
inhibits the invasiveness of inflammatory breast cancer cells in vitro. J Cancer Res
Clin Oncol 133(2), 83–92.
[23] Kleer CG, van Golen KL, and Braun T, et al (2001). Persistent E-cadherin
expression in inflammatory breast cancer. Mod Pathol 14(5), 458–464.
[24] Tomlinson JS, Alpaugh ML, and Barsky SH (2001). An intact overexpressed
E-cadherin/alpha, beta-catenin axis characterizes the lymphovascular emboli of
inflammatory breast carcinoma. Cancer Res 61(13), 5231–5241.
[25] Christiansen JJ and Rajasekaran AK (2006). Reassessing epithelial to
mesenchymal transition as a prerequisite for carcinoma invasion and metastasis.
Cancer Res 66(17), 8319–8326.
[26] Moreno-Bueno G, Portillo F, and Cano A (2008). Transcriptional regulation of
cell polarity in EMT and cancer. Oncogene 27(55), 6958–6969.
[27] Mani SA, Guo W, and Liao MJ, et al (2008). The epithelial-mesenchymal
transition generates cells with properties of stem cells. Cell 133(4), 704–715.
[28] Sheridan C, Kishimoto H, and Fuchs RK, et al (2006). CD44+/CD24- breast
cancer cells exhibit enhanced invasive properties: an early step necessary for
metastasis. Breast Cancer Res 8(5), R59.
Translational Oncology Vol. 8, No. 5, 2015 Wurth et al. 367[29] Abraham BK, Fritz P, and McClellan M, et al (2005). Prevalence of
CD44+/CD24-/low cells in breast cancer may not be associated with clinical
outcome but may favor distant metastasis. Clin Cancer Res 11(3), 1154–1159.
[30] Bos PD, Nguyen DX, andMassague J (2010). Modeling metastasis in the mouse.
Curr Opin Pharmacol 10(5), 571–577.
[31] Liu KK and Dorovini-Zis K (2009). Regulation of CXCL12 and CXCR4
expression by human brain endothelial cells and their role in CD4+ and CD8+ T
cell adhesion and transendothelial migration. J Neuroimmunol 215(1-2), 49–64.
[32] Sun X, Cheng G, and Hao M, et al (2010). CXCL12 / CXCR4 / CXCR7
chemokine axis and cancer progression. Cancer Metastasis Rev 29(4),
709–722.
[33] Miao Z, Luker KE, and Summers BC, et al (2007). CXCR7 (RDC1) promotes
breast and lung tumor growth in vivo and is expressed on tumor-associated
vasculature. Proc Natl Acad Sci U S A 104(40), 15735–15740.
[34] Singh B, Cook KR, and Martin C, et al (2010). Evaluation of a CXCR4
antagonist in a xenograft mouse model of inflammatory breast cancer. Clin Exp
Metastasis 27(4), 233–240.
[35] Shimizu S, Brown M, and Sengupta R, et al (2011). CXCR7 protein expression
in human adult brain and differentiated neurons. PLoS One 6(5), e20680.[36] Naumann U, Cameroni E, and Pruenster M, et al (2010). CXCR7 functions as a
scavenger for CXCL12 and CXCL11. PLoS One 5(2), e9175.
[37] Wojcechowskyj JA, Lee JY, and Seeholzer SH, et al (2011). Quantitative
phosphoproteomics of CXCL12 (SDF-1) signaling. PLoS One 6(9), e24918.
[38] Hatse S, Princen K, and Bridger G, et al (2002). Chemokine receptor inhibition
by AMD3100 is strictly confined to CXCR4. FEBS Lett 527(1-3), 255–262.
[39] Luker KE, Gupta M, and Steele JM, et al (2009). Imaging ligand-dependent
activation of CXCR7. Neoplasia 11(10), 1022–1035.
[40] Kakinuma T and Hwang ST (2006). Chemokines, chemokine receptors, and
cancer metastasis. J Leukoc Biol 79(4), 639–651.
[41] Lee BC, Lee TH, and Avraham S, et al (2004). Involvement of the chemokine
receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer
cell migration through human brain microvascular endothelial cells. Mol Cancer
Res 2(6), 327–338.
[42] Furusato B, Mohamed A, and Uhlen M, et al (2010). CXCR4 and cancer. Pathol
Int 60(7), 497–505.
[43] Zeelenberg IS, Ruuls-Van Stalle L, and Roos E (2003). The chemokine receptor
CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer
Res 63(13), 3833–3839.
